Immunotherapy for gastrointestinal malignancies: the journey does not end here!

Por Almhanna, Khaldoun
Publicado no Transl Gastroenterol Hepatol (2020)

Editorial for the series on gastric and gastroesophageal cancer treatment in 2020

Por Almhanna, Khaldoun
Publicado no Ann Transl Med (2020)

Current status of novel agents in advanced gastroesophageal adenocarcinoma

Por Kothari, Nishi, Almhanna, Khaldoun
Publicado no J Gastrointest Oncol (2015)

Esophageal cancer 2015, more questions than answers

Por Almhanna, Khaldoun, Hoffe, Sarah
Publicado no J Gastrointest Oncol (2015)

Large rib osteochondroma in a child in Aleppo, Syria

Por Alhames, Samer, Almhanna, Khaldoun
Publicado no J Surg Case Rep (2018)

Predictive markers in gastric cancer immunotherapy treatment—are we there yet?

Por Mehta, Rutika, Almhanna, Khaldoun
Publicado no Transl Gastroenterol Hepatol (2019)

Esophageal, gastric cancer and immunotherapy: small steps in the right direction?

Por Zayac, Adam, Almhanna, Khaldoun
Publicado no Transl Gastroenterol Hepatol (2020)

Hepatobiliary cancers and immunotherapy: where are we now and where are we heading?

Por Zayac, Adam, Almhanna, Khaldoun
Publicado no Transl Gastroenterol Hepatol (2020)

Locoregional gastric cancer: a narrative review of multidisciplinary management

Por Pelcovits, Ari, Almhanna, Khaldoun
Publicado no Ann Transl Med (2020)

Pancreatic cancer and immune checkpoint inhibitors—still a long way to go

Por Bian, Jessica, Almhanna, Khaldoun
Publicado no Transl Gastroenterol Hepatol (2021)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma

Por Almhanna, Khaldoun, Philip, Philip A
Publicado em 2009

Multimodality approach for locally advanced esophageal cancer

Por Almhanna, Khaldoun, Strosberg, Jonathan R
Publicado em 2012

Immune checkpoint inhibitors for esophageal cancer: are we moving in the right direction?

Por Raufi, Alexander G., Almhanna, Khaldoun
Publicado no Ann Transl Med (2019)

Anal cancer and immunotherapy—are we there yet?

Por Bian, Jessica J., Almhanna, Khaldoun
Publicado no Transl Gastroenterol Hepatol (2019)

Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy

Por Mehta, Rutika, Shah, Anand, Almhanna, Khaldoun
Publicado no Onco Targets Ther (2018)

Does tumor profile in gastric and gastroesophageal (GE) junction cancer justify off-label use of targeted therapy?—a narrative review

Por Del Prete, Christopher, Muthiah, Arun, Almhanna, Khaldoun
Publicado no Ann Transl Med (2020)

Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?

Por Shah, Anand B., Sommerer, Katelyn R., Almhanna, Khaldoun
Publicado no Transl Gastroenterol Hepatol (2019)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020

Por Hsu, Andrew, Zayac, Adam S., Eturi, Aditya, Almhanna, Khaldoun
Publicado no Ann Transl Med (2020)

Targeted therapies for gastroesophageal cancers

Por Hsu, Andrew, Chudasama, Rani, Almhanna, Khaldoun, Raufi, Alexander
Publicado no Ann Transl Med (2020)

Palliative care for patients with esophageal cancer: a narrative review

Por Guyer, Dana L., Almhanna, Khaldoun, McKee, Kanako Y.
Publicado no Ann Transl Med (2020)